<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

AACR 2022 Poster 3115

Establishment and Characterization of a Panel of Advanced Breast Cancer Patient-Derived Xenograft (PDX) Models for Cancer Therapeutic Evaluation

Leilei Chen, Xueying Yang, Likun Zhang, Xiaobo Chen, Henry Q.X. Li, Jessie J.J. Wang

Despite the progress and development of targeted agents and immunotherapeutics, there is a high unmet need for treatments of triple negative breast cancer (TNBC) and relapsed breast cancers with specific mutations. Breast cancer is a highly heterogeneous disease and reliable models are needed to develop new clinical therapies and better reflect tumor biology.

Patient-derived xenograft (PDX) models have been widely used for understanding tumor characteristics and represent human heterogeneity more faithfully and thus are suitable for mouse clinical studies for predicting drug efficacy in the clinic. Here we report the establishment and characterization of a panel of breast cancer PDX models for preclinical research.

Download this Poster to Discover:

  • The newly established and characterized breast Cancer PDX models representing a range of ER/PR/HER2 expression statuses, including primary and advanced cancer

  • The different rates of tumor growth in these PDX models with or without estrogen, and different responses to current treatments like fulvestrant, paclitaxel, and PARP Inhibitor

  • The relevant clinical, genetic, and genomic data associated with these new Breast Cancer PDX models.

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.